Alnylam Pharmace. sell Biotechhunter
Start price
31.07.20
/
50%
€125.52
Target price
06.08.20
-
Performance (%)
-3.39%
End price
06.08.20
€121.26
Summary
This prediction ended on 06.08.20 with a price of €121.26. With a performance of -3.39%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -0.653% | -0.653% | 14.495% | 43.039% |
| iShares Core DAX® | -0.121% | 2.507% | 16.129% | 61.530% |
| iShares Nasdaq 100 | 0.081% | -0.241% | 4.636% | 97.770% |
| iShares Nikkei 225® | -1.748% | 4.105% | 16.103% | 48.713% |
| iShares S&P 500 | -0.961% | -0.143% | 1.644% | 62.430% |